Pharmaceutical Preparations · DE · CIK 1672619
Develops small molecule therapeutics targeting cancer-driving genes like BCR-ABL and HER2
Comparable business profile · signals at a glance
In the 90 days to Mar 25, 2026: 5 sold $10.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 | $1.4M |
| Mar 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 | $139K |
| Mar 10, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 10,129 | $30.19 | $306K |
| Mar 9, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 29,871 | $30.02 | $897K |
| Mar 6, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER | Sell | 10,000 | $29.58 | $296K |
| Feb 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.2M |
| Feb 17, 2026 | Heyman Richard A.Director | Sell | 1,230 | $26.18 | $32K |
| Feb 6, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145K |
| Jan 20, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 14,509 | $26.90 | $390K |
| Jan 20, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 5,491 | $26.37 | $145K |
| Jan 20, 2026 | Heyman Richard A.Director | Sell | 718 | $26.96 | $19K |
| Jan 20, 2026 | Heyman Richard A.Director | Sell | 512 | $26.46 | $14K |
| Jan 9, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 50,000 | $29.13 | $1.5M |
| Jan 9, 2026 | Patel AnishCHIEF OPERATING OFFICER | Sell | 48,057 | $27.98 | $1.3M |
| Jan 9, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 41,198 | $24.90 | $1.0M |
| Jan 9, 2026 | Heyman Richard A.Director | Sell | 4,285 | $25.00 | $107K |
| Jan 9, 2026 | Patel AnishCHIEF OPERATING OFFICER | Sell | 243 | $28.50 | $7K |
| Jan 8, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 33,802 | $24.92 | $842K |
| Jan 8, 2026 | Heyman Richard A.Director | Sell | 8,015 | $25.04 | $201K |
| Jan 8, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 7,500 | $20.13 | $151K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.